drugset / Trial / NCT00018148

Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

NCT00018148

Phase 2 Completed 158 enrolled US Department of Veterans Affairs
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.

Timeline

Start
1998-04
Primary completion
2002-12
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nortriptyline Small molecule 75 mg Oral
Comparator Nicotine Unknown 21 mg Other

Indications

No indication recorded.